Impact of switching from intravenous to oral linezolid therapy in Japanese patients: a retrospective cohort study.
J Pharm Policy Pract. 2016;9:35
Authors: Tanaka A, Yano A, Watanabe S, Tanaka M, Araki H
BACKGROUND: High oral bioavailability of antimicrobial agents can result in the replacement of intravenous (IV) therapy with oral therapy when a patient meets defined clinical criteria. However, few studies have evaluated the effects of switching antibiotic administration route in Japan, especially for linezolid. This study evaluated an IV-to-oral antibiotic switching program for linezolid treatment at a university hospital in Japan.
METHODS: In a retrospective cohort study of 73 patients, we assessed the efficacy and safety of IV-to-oral linezolid therapy (n = 21 patients) compared with IV therapy alone (n = 52 patients).
RESULTS: Duration of linezolid treatment, changes in C-reactive protein or platelet count from baseline, re-administration of anti-methicillin-resistant Staphylococcus aureus agent within 90 days of discharge, and mortality within 28 days of discharge were not significantly different between the two groups.
CONCLUSIONS: An IV-to-oral switching program could reduce the duration of IV linezolid therapy without worsening clinical outcomes in Japanese patients receiving linezolid therapy.
PMID: 27795831 [PubMed - in process]